Safety qualms in MyoKardia mid-stage study cause investors to pause

Safety qualms in MyoKardia mid-stage study cause investors to pause

Source: 
Endpoints
snippet: 

Ahead of the pivotal data readout of MyoKardia’s lead drug, mavacamten, in patients with obstructive hypertrophic cardiomyopathy (HCM), investors took issue with the drug’s safety profile in a separate Phase II non-obstructive HCM study.